Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Bfsg LLC

Bfsg LLC reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,680 shares of the company’s stock after selling 860 shares during the period. Bfsg LLC’s holdings in Teva Pharmaceutical Industries were worth $153,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 6.9% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after purchasing an additional 1,860,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 3.0% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 28,533,099 shares of the company’s stock valued at $297,886,000 after acquiring an additional 821,759 shares in the last quarter. Rubric Capital Management LP grew its stake in shares of Teva Pharmaceutical Industries by 1.5% during the third quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $193,800,000 after acquiring an additional 281,638 shares in the last quarter. AustralianSuper Pty Ltd grew its stake in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company’s stock valued at $94,368,000 after acquiring an additional 1,431,671 shares in the last quarter. Finally, Sound Shore Management Inc CT acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at about $80,791,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.01 during mid-day trading on Thursday, reaching $13.02. 2,653,853 shares of the stock traded hands, compared to its average volume of 10,478,676. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $14.47. The business has a 50-day moving average of $13.50 and a two-hundred day moving average of $11.34. The firm has a market capitalization of $14.60 billion, a PE ratio of -27.68, a P/E/G ratio of 1.56 and a beta of 1.05.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The company had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $3.97 billion. As a group, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TEVA. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a research note on Friday, March 8th. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their target price for the company from $12.00 to $19.00 in a research note on Monday, February 12th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their target price for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.78.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CEO Richard D. Francis sold 74,530 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Richard D. Francis sold 74,530 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now directly owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock worth $5,132,766 over the last ninety days. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.